Nature Communications (Jul 2024)

Rational correction of pathogenic conformational defects in HTRA1

  • Nathalie Beaufort,
  • Linda Ingendahl,
  • Melisa Merdanovic,
  • Andree Schmidt,
  • David Podlesainski,
  • Tim Richter,
  • Thorben Neumann,
  • Michael Kuszner,
  • Ingrid R. Vetter,
  • Patricia Stege,
  • Steven G. Burston,
  • Anto Filipovic,
  • Yasser B. Ruiz-Blanco,
  • Kenny Bravo-Rodriguez,
  • Joel Mieres-Perez,
  • Christine Beuck,
  • Stephan Uebel,
  • Monika Zobawa,
  • Jasmin Schillinger,
  • Rainer Malik,
  • Katalin Todorov-Völgyi,
  • Juliana Rey,
  • Annabell Roberti,
  • Birte Hagemeier,
  • Benedikt Wefers,
  • Stephan A. Müller,
  • Wolfgang Wurst,
  • Elsa Sanchez-Garcia,
  • Alexander Zimmermann,
  • Xiao-Yu Hu,
  • Tim Clausen,
  • Robert Huber,
  • Stefan F. Lichtenthaler,
  • Carsten Schmuck,
  • Michael Giese,
  • Markus Kaiser,
  • Michael Ehrmann,
  • Martin Dichgans

DOI
https://doi.org/10.1038/s41467-024-49982-8
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 18

Abstract

Read online

Abstract Loss-of-function mutations in the homotrimeric serine protease HTRA1 cause cerebral vasculopathy. Here, we establish independent approaches to achieve the functional correction of trimer assembly defects. Focusing on the prototypical R274Q mutation, we identify an HTRA1 variant that promotes trimer formation thus restoring enzymatic activity in vitro. Genetic experiments in Htra1 R274Q mice further demonstrate that expression of this protein-based corrector in trans is sufficient to stabilize HtrA1-R274Q and restore the proteomic signature of the brain vasculature. An alternative approach employs supramolecular chemical ligands that shift the monomer-trimer equilibrium towards proteolytically active trimers. Moreover, we identify a peptidic ligand that activates HTRA1 monomers. Our findings open perspectives for tailored protein repair strategies.